98 related articles for article (PubMed ID: 11519066)
41. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
42. Enhanced recovery after surgery for gastric cancer and an assessment of preoperative carbohydrate loading.
Makuuchi R; Sugisawa N; Kaji S; Hikage M; Tokunaga M; Tanizawa Y; Bando E; Kawamura T; Terashima M
Eur J Surg Oncol; 2017 Jan; 43(1):210-217. PubMed ID: 27554250
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
44. Comparison of postoperative lymphocytes and interleukins between laparoscopy-assisted and open radical gastrectomy for early gastric cancer.
Xia X; Zhang Z; Xu J; Zhao G; Yu F
J Int Med Res; 2019 Jan; 47(1):303-310. PubMed ID: 30270803
[TBL] [Abstract][Full Text] [Related]
45. Lymphocyte-to-monocyte ratios predict gastric cancer surgical outcomes.
Hsu JT; Wang CC; Le PH; Chen TH; Kuo CJ; Lin CJ; Chou WC; Yeh TS
J Surg Res; 2016 May; 202(2):284-90. PubMed ID: 27229102
[TBL] [Abstract][Full Text] [Related]
46. [Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma].
Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Tancini G; Andres M; Favini P; Scardino E; Rocco F
Arch Ital Urol Androl; 1997 Jun; 69(3):159-62. PubMed ID: 9273090
[TBL] [Abstract][Full Text] [Related]
47. [Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
Viganò MG; Lissoni P; Barni S; Tancini G; Scardino E; Favini P; Baccalini A; Verweij F; Strada G; Rocco F
Arch Ital Urol Androl; 1995 Apr; 67(2):143-7. PubMed ID: 7787856
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
49. Alteration of hypothalamus-pituitary-adrenal glands axis in colorectal cancer patients.
Mussi C; Angelini C; Crippa S; Caprotti R; Fumagalli L; Motta V; Uggeri F
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxxviii-ccxxxi. PubMed ID: 15244187
[TBL] [Abstract][Full Text] [Related]
50. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
51. Cellular and peritoneal immune response after radical laparoscopy-assisted and open gastrectomy for gastric cancer.
Jung IK; Kim MC; Kim KH; Kwak JY; Jung GJ; Kim HH
J Surg Oncol; 2008 Jul; 98(1):54-9. PubMed ID: 18521842
[TBL] [Abstract][Full Text] [Related]
52. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
[TBL] [Abstract][Full Text] [Related]
53. Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial.
Li Y; Yang GL; Yuan HY; Bai DJ; Wang K; Lin CR; Hu MB; Feng MH
Hepatogastroenterology; 2005; 52(62):504-8. PubMed ID: 15816467
[TBL] [Abstract][Full Text] [Related]
54. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial.
Lin CY; Bai DJ; Yuan HY; Wang K; Yang GL; Hu MB; Wu ZQ; Li Y
World J Gastroenterol; 2004 Jan; 10(1):136-42. PubMed ID: 14695785
[TBL] [Abstract][Full Text] [Related]
55. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
56. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
57. Lymphocytic subpopulation changes after open and laparoscopic cholecystectomy: a prospective and comparative study on 38 patients.
Cristaldi M; Rovati M; Elli M; Gerlinzani S; Lesma A; Balzarotti L; Taschieri AM
Surg Laparosc Endosc; 1997 Jun; 7(3):255-61. PubMed ID: 9194291
[TBL] [Abstract][Full Text] [Related]
58. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
59. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Brivio F; Lissoni P; Alderi G; Barni S; Lavorato F; Fumagalli L
Oncology; 1996; 53(4):263-8. PubMed ID: 8692528
[TBL] [Abstract][Full Text] [Related]
60. [Feasibility and tolerance evaluation of 2 routes of preoperative administration of interleukin 2].
Houvenaeghel G; Blache JL; Arnaud S; Bladou F; Brun JP; Chaudet H; Oskam R; Delpero JR; Guerinel G
Bull Cancer; 1995 Dec; 82(12):1052-9. PubMed ID: 8745672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
